A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

• Locally advanced unresectable, recurrent, and/or metastatic HCC
• Must have progressed on 1st line therapy that contained anti-PD-1 or anti-PD-L1 therapy as their immediate prior treatment regimen
• Child-Pugh A determined withint 14 days of first treatment
• All patients must undergo EGD with esophageal varices assessment
• Measurable and injectable disease
• Must be willing to undergo biopsy
• ECOG PS 0-1
• No significant bleeding event in last 12 months
• No macroscopic vascular invastion into major blood vessels
• No rare HCC variants
• No liver tumors that are estimated to invade more than one-third of the liver
• No known acute or chronic HBV/HCV unless PCR below lower limits of detection
• No known HIV
• No known CNS metastatses

• Primary
  • ORR
• Secondary
  • AEs
  • ORR per HCC modified RECIST
  • DoR